STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [EFFECT] Spyre Therapeutics, Inc. SEC Filing

[EFFECT] Spyre Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: February 27, 2026 4:00 P.M.
Form: S-3
CIK: 0001636282
Company Name: Spyre Therapeutics, Inc.
File Number: 333-293600

Source: View Original Filing on SEC EDGAR

Stock SYRE logo
Spyre Therapeutics

NASDAQ:SYRE

SYRE Rankings

#1770 Ranked by Market Cap
N/A Ranked by Dividends

SYRE Latest News

Feb 24, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Feb 19, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 18, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Feb 6, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Jan 23, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

SYRE Latest SEC Filings

Mar 3, 2026
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Mar 3, 2026
[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity
Mar 3, 2026
[144] Spyre Therapeutics, Inc. SEC Filing
Mar 2, 2026
[144] Spyre Therapeutics, Inc. SEC Filing
Feb 27, 2026
[POS AM] Spyre Therapeutics, Inc. SEC Filing

SYRE Stock Data

3.34B
70.98M
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM